Telaglenastat hydrochloride is under clinical development by Calithera Biosciences and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Telaglenastat hydrochloride’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 18 Feb 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Telaglenastat hydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Telaglenastat hydrochloride overview

Telaglenastat hydrochloride is under development for the treatment of non-small cell lung cancer, soft tissue sarcoma, malignant peripheral nerve sheath tumors, pancreatic ductal adenocarcinoma ,metastatic melanoma, myelodysplastic syndrome, metastatic colorectal cancer, gastrointestinal stromal tumors( GIST) including succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST), tumors harboring mutations in isocitrate dehydrogenase-1 (IDH1) or IDH2, fumarate hydratase (FH)-deficient tumors, SDH-deficient non-GIST tumors, cervical cancer and IDH-mutated diffuse or anaplastic astrocytoma. It is formulated both as a capsule and tablet which is administered through oral route. The drug candidate acts by targeting glutaminase enzyme.

It was also under development for the treatment of metastatic castration-resistant prostate cancer (mCRPC), metastatic triple-negative breast cancer (TNBC), relapsed/refractory acute myeloid leukemia, relapsed/refractory acute lymphocytic leukemia, relapsed/refractory multiple myeloma, non-Hodgkin lymphoma, Waldenstrom's macroglobulinemia and metastatic renal cell carcinoma.

Calithera Biosciences overview

Calithera Biosciences (Calithera) is a clinical-stage bio-pharmaceutical company that discovers and develops novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The company’s product pipeline includes CB-839, a glutaminase inhibitor in tumor metabolism to treat solid tumors, NCB001158, a small molecule arginase inhibitor based on tumor immunology technology that activates the body’s own immune system to attack and kill cancer cells for the treatment of hematology and oncology diseases, CB-280, a arginase inhibitor used for treating Cystic Fibrosis, CB-708, a CD73 inhibitor against immuno-oncology conditions and IL4I1 Inhibitor CB-668 against immuno-oncology conditions. The company works in collaboration with bio-pharmaceutical companies such as Incyte Corp, Bristol-Myers Squibb (BMS), and Mars Symbiosciences Inc. Calithera is headquartered in South San Francisco, California, the US.

Quick View Telaglenastat hydrochloride LOA Data

Report Segments
  • Innovator
Drug Name
  • Telaglenastat hydrochloride
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.